{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"}],"units":"Participants"}],"description":"The percentage of participants reporting STS specific adverse events will be measured by affirmative responses on the PRO-CTCAE® on any of the selected oral, gastrointestinal, neurologic and visual/perceptual symptoms.","groups":[{"description":"Participants undergo standard of care radiation therapy daily in combination with cisplatin on day 1. Between 4-5 hours after each cisplatin infusion, patients also receive sodium thiosulfate over 1-2 hours on day 1. Treatment will continue on either a 1 week or 3 week cycle per physician discretion for up to 6-7 weeks in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Cisplatin, Radiotherapy, STS"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Up to 18 weeks","title":"Percentage of Participants Reporting Sodium Thiosulfate (STS)-Specific Symptomology","type":"SECONDARY","unitOfMeasure":"percentage of participants"}